Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A new oral direct thrombin inhibitor—ximelagatran (Exanata; Astra-Zeneca)—steals the stage at this year’s American College of Cardiology 52nd Scientific Session in Chicago.

Late Breakers